Related Experiment Videos
Hyperfractionated radiotherapy for Burkitt-type lymphoma. Radiobiological aspects
B Pilecki1, P Kopiec, A Zajusz
1Center for Oncology, Maria Sklodowska-Curie, Memorial Institute, Gliwice, Poland.
Neoplasma
|January 1, 1991
Summary
Accelerated hyperfractionated irradiation combined with COP chemotherapy showed potential for Burkitt-type lymphoma treatment. However, rapid tumor repopulation necessitates more frequent irradiation and chemotherapy intervals for optimal outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Burkitt-type lymphoma is an aggressive non-Hodgkin lymphoma characterized by rapid proliferation.
- Standard treatment protocols often involve chemotherapy and radiation therapy.
Observation:
- A case study evaluated accelerated hyperfractionated irradiation with COP chemotherapy for Burkitt-type lymphoma.
- Tumor volume doubling time decreased from 15 to 4.5 days, indicating accelerated tumor growth during treatment.
- A surviving fraction of 10(-19) was calculated after 58 Gy in a twice-daily regimen, suggesting potential for local tumor control.
Findings:
- Despite initial indicators of tumor control, only partial remission was achieved.
- Accelerated tumor repopulation by surviving clonogenic cells is hypothesized as the reason for non-radical effects.
- The calculated effective dose (effDo) was 1.37 Gy.
Implications:
- Fast-growing tumors like Burkitt-type lymphoma may require more intensive treatment schedules.
- Irradiation with three fractions per day, instead of two, combined with chemotherapy at shorter intervals could improve outcomes.
- Further research into optimized radiation fractionation and chemotherapy timing is warranted for aggressive lymphomas.